— Know what they know.
Not Investment Advice

GENO.ST STO

Genovis AB
1W: +3.0% 1M: -9.1% 3M: +1.8% YTD: -0.4% 1Y: -19.8% 3Y: -55.9% 5Y: -65.0%
kr 19.54 ($1.94)
-0.14 (-0.71%)
 
Weekly Expected Move ±4.8%
kr 18 kr 19 kr 20 kr 20 kr 21
STO · Healthcare · Biotechnology · Tech Score Neutral · Power 49 · kr 1.3B mcap · 57M float · 0.189% daily turnover

Balance Sheet Trends

Total Assets
$378M +15.4% ▲
5Y CAGR: +28.8%
Total Liabilities
$106M +7.0% ▲
5Y CAGR: +40.4%
Shareholders Equity
$272M +19.1% ▲
5Y CAGR: +25.5%
Cash & Investments
$163M -3.7% ▼
5Y CAGR: +29.9%
Total Debt
$140M +82.6% ▲
5Y CAGR: +83.8%
Net Debt
-$23M +74.8% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2021FY2022FY2023FY2024FY2025
— Assets —
Cash$81M$73M$123M$169M$163M
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$81M$73M$123M$169M$163M
Net Receivables$13M$17M$15M$21M$0
Inventory$12M$13M$15M$13M$0
Other Current Assets$2M$2M$3M-$1K$43M
Total Current Assets$109M$107M$159M$208M$207M
Property, Plant & Equip.$10M$16M$95M$89M$84M
Goodwill & Intangibles$16M$17M$17M$8M$79M
Long-Term Investments$77K$89K$0$11M$129K
Other Non-Current Assets$0$0$86K$1K$0
Total Non-Current Assets$33M$44M$130M$119M$171M
Total Assets$142M$151M$289M$327M$378M
— Liabilities —
Accounts Payable$3M$5M$4M$3M$0
Short-Term Debt-$2M$0$0$0$6M
Deferred Revenue$19M$640K$0$0$0
Other Current Liabilities$895K$3M$5M$19M$22M
Total Current Liabilities$24M$18M$21M$28M$28M
Long-Term Debt$0$0$0$0$67M
Other Non-Current Liab.$0-$367$0$0-$61M
Total Non-Current Liabilities$4M$7M$77M$71M$78M
Total Liabilities$28M$25M$98M$99M$106M
— Equity —
Common Stock$16M$16M$16M$16M$17M
Retained Earnings-$116M-$105M-$44M-$11M$0
Accumulated OCI-$2M-$1M$3M$7M$0
Total Stockholders Equity$114M$126M$191M$228M$272M
Total Liabilities & Equity$142M$151M$289M$327M$378M
— Key Metrics —
Total Debt$3M$7M$79M$77M$140M
Net Debt-$78M-$66M-$44M-$93M-$23M
Total Investments$77K$89K$0$11M$129K

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms